Letter by Romanens and Miserez Regarding Article, “Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months: A Multicenter, Randomized, Double-Blind Trial”

Abstract

To the Editor: We read with great interest the report by Schmermund et al1 that failed to demonstrate a difference in progression of coronary calcium (CAC) in asymptomatic, nondiseased subjects when treated with 10 mg versus 80 mg atorvastatin for 12 months. The authors expected that in 471 patients, a significantly lower progression of CAC scores and differences between groups of patients treated with 10 mg versus 80 mg atorvastatin could be observed. The study by Schmermund et …